High Dose BDPP for Healthy Controls

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Healthy Controls
Trans-resveratrol - DietarySupplement
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study the effects of a dietary supplement on the body. The supplement is a mixture of Concord grape juice, grape seed extract, and resveratrol.

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: up to Week 5

up to Week 5
DHCA level
IL-6 levels

Trial Safety

Trial Design

4 Treatment Groups

High Dose BDPP
1 of 4
Low Dose BDPP
1 of 4
Medium Dose BDPP
1 of 4
Placebo
1 of 4
Active Control
Non-Treatment Group

88 Total Participants · 4 Treatment Groups

Primary Treatment: High Dose BDPP · Has Placebo Group · Phase 1

Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
High Dose BDPPActiveComparator Group · 3 Interventions: Trans-resveratrol, Grape seed polyphenol extract, Concord grape juice · Intervention Types: DietarySupplement, DietarySupplement, DietarySupplement
Low Dose BDPPActiveComparator Group · 3 Interventions: Trans-resveratrol, Grape seed polyphenol extract, Concord grape juice · Intervention Types: DietarySupplement, DietarySupplement, DietarySupplement
Medium Dose BDPPActiveComparator Group · 3 Interventions: Trans-resveratrol, Grape seed polyphenol extract, Concord grape juice · Intervention Types: DietarySupplement, DietarySupplement, DietarySupplement

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to week 5

Who is running the clinical trial?

National Center for Complementary and Integrative Health (NCCIH)NIH
771 Previous Clinical Trials
642,938 Total Patients Enrolled
1 Trials studying Healthy Controls
73 Patients Enrolled for Healthy Controls
Icahn School of Medicine at Mount SinaiLead Sponsor
771 Previous Clinical Trials
479,755 Total Patients Enrolled
James Murrough, MD, PhD4.04 ReviewsPrincipal Investigator - Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
4 Previous Clinical Trials
149 Total Patients Enrolled
5Patient Review
Dr. Murrough is always willing to listen, and I appreciate his thoroughness and expertise. I've been with him for several years now, and he has always been sensitive to my needs.

Eligibility Criteria

Age 18 - 65 · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
People aged 18-55 years old can be male or female.
The participants must be able to understand English well enough to agree to all the tests and examinations required by the study, and they must also be able to participate fully in the informed consent process.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: October 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
New York100.0%
How old are they?
18 - 65100.0%
What site did they apply to?
Icahn School of Medicine at Mount Sinai100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%

How responsive is this trial?

Typically responds via
Email100.0%